Clinical trial Recruiting at 1 site Interventional Ages 18 to 50 Men only

taVNS for relieving symptoms of moderate-to-severe chronic prostatitis/CPPS

Official title: Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Moderate to Severe Chronic Prostatitis/Chronic Pelvic Pain Syndrome (TASC-P Trial): a Randomized, Sham Controlled Trial.

Run by Guang'anmen Hospital of China Academy of Chinese Medical Sciences · NCT06287970 · Data updated 2026-11-12

This trial will try transcutaneous auricular vagus nerve stimulation (taVNS) to see if it reduces pain and urinary and mood symptoms in adults aged 18–50 with moderate to severe chronic prostatitis/CPPS.

More Chronic Prostatitis trials

Quick facts

Study typeInterventional
Ages18 Years to 50 Years
SexMen only
Enrollment68 (estimated)
SponsorGuang'anmen Hospital of China Academy of Chinese Medical Sciences
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedMarch 15, 2024
Main results expectedDecember 31, 2026
Study endsFebruary 18, 2027
Registry record updatedNovember 28, 2025
Trial IDNCT06287970 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–50 diagnosed with CP/CPPS (symptoms >3 months in the last 6 months) with NIH-CPSI score ≥15, without infection or other clear pathological causes, are the intended participants.

Probably not a fit

People outside the 18–50 age range, those with infectious or other identifiable causes of pelvic pain, or those with only mild CP/CPPS symptoms (NIH-CPSI <15) are unlikely to benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized, sham-controlled trial enrolling 68 patients with moderate-to-severe CP/CPPS who meet EAU/CAU diagnostic criteria. Participants will be randomized 1:1 to receive either active taVNS or a sham taVNS intervention for 4 weeks, with an 8-week follow-up after treatment. Outcomes include NIH-CPSI, IPSS, EQ-5D, and measures of anxiety and depression (SAS, SDS), and adverse events will be recorded throughout. The trial is conducted at Guang'anmen Hospital, China Academy of Chinese Medical Sciences in Beijing.

Why it matters

Potential benefit: If successful, taVNS could offer a noninvasive treatment option to reduce pelvic pain and improve urinary symptoms and quality of life for people with CP/CPPS.

How similar studies have gone: Noninvasive vagus nerve stimulation has shown promise for some chronic pain and mood disorders, but applying taVNS specifically to CP/CPPS is relatively novel with limited prior data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Consistent with the diagnostic criteria of CP/CPPS of EAU or CAU, the clinical manifestations were recurrent and persistent prostate pain accompanied by abnormal urination and psychiatric symptoms, without infection or other obvious pathological conditions. The pain symptoms were mainly manifested as pain in the surrounding tissues centered on the prostate, and pain, swelling or discomfort in the scrotum, testis, lower abdomen, perineum, lumbosacral area, and medial thigh. Abnormal urination was characterized by frequent urination, urgent urination, urination pain, urethral burning, residual urination or white discharge from the urethra at the end of urination or defecation in the morning. The neuropsychiatric symptoms included dizziness and tinnitus, insomnia and dreams, anxiety and depression, and even impotence, premature ejaculation, and spermatorrhea. Symptoms lasting more than 3 months in the last six months
* 18 ≤ Age ≤ 50 years old
* NIH-CPSI ≥15 (patients with moderate to severe CP/CPPS)
* Signed informed consent and voluntarily participated in the trial

Exclusion Criteria:

* Patients with other diseases that cause urinary symptoms were excluded: Such as benign prostatic hyperplasia, testicular and epididymal and spermatic cord diseases, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumors such as carcinoma in situ, prostate cancer, urinary male reproductive system tuberculosis, anorectal diseases, lumbar diseases, central and peripheral neuropathy, etc
* Patients with severe diseases of the heart, liver, kidney, hematopoietic system and poor nutritional status
* Patients with severe mental and emotional disorders, who were unable to cooperate with the study
* Patients who have been treated with CP/CPPS regimen in the past 4 weeks

Where it's running

  • Guang'anmen Hospita, China Academy of Chinese Medical Sciences
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.